2022. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s4. DOI:https://doi.org/10.25251/skin.6.supp.4.